RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: RAD001(Everolimus) may stop the growth of cancer cells by blocking some of the
enzymes needed for their growth and by blocking blood flow to the cancer.
PURPOSE: This phase II trial is studying how well RAD001(everolimus) works in treating
patients with myelodysplastic syndromes.